Vivek RamaswamyFounder & CEO at Roivant Sciences
Vivek Ramaswamy is the Founder and Chief Executive Officer of Roivant Sciences. Roivant is a new type of biopharma company focused on the application of technology to drug development. Roivant has developed over 40 medicines, delivered four successful Phase 3 studies in 2019, and recently signed a $3B+ partnership with a large Japanese pharma company.
Vivek graduated summa cum laude in Biology from Harvard College and began his career as a successful biotech investor where he led successful investments in companies developing early-stage therapeutics including the eventual cure for chronic hepatitis C virus. He continued to work as an investor while earning his law degree at Yale Law School, where he was a recipient of the Paul & Daisy Soros Fellowship.
Vivek has authored numerous articles and op-eds, which have appeared in The Wall Street Journal, The New York Times, and Harvard Business Review.